Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients | Zendy

Lauren Fontana | Zendy; David S. Perlin | Zendy; Yanan Zhao | Zendy; Brie N. Noble | Zendy; James S. Lewis | Zendy; Lynne Strasfeld | Zendy; Morgan Hakki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients

Author(s) -

Lauren Fontana,

David S. Perlin,

Yanan Zhao,

Brie N. Noble,

James S. Lewis,

Lynne Strasfeld,

Morgan Hakki

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz282

Subject(s) - medicine , posaconazole , neutropenia , voriconazole , mucormycosis , incidence (geometry) , aspergillosis , hematopoietic stem cell transplantation , acute leukemia , surgery , transplantation , leukemia , immunology , antifungal , chemotherapy , dermatology , physics , optics

Isavuconazole (ISA) is an attractive candidate for primary mold-active prophylaxis in high-risk patients with hematologic malignancies or hematopoietic cell transplant (HCT) recipients. However, data supporting the use of ISA for primary prophylaxis in these patients are lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research